Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus camrelizumab for third-line MSS advanced colorectal cancer
ChiCTR2100048528Phase 2Not yet recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and fruquintinib in colorectal cancer (CRC), sponsored by Anhui Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
camrelizumabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100048528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048528.